Deep vein thrombosis prophylaxis use in traumatic brain injury patients in tropical climate

Abstract

Deep Vein Trombosis (DVT) is one of the extracranial complications after TBI. Prophylaxis DVT using on TBI reduce incidence and mortality. Climate variants of an area affect the risk of DVT. UV ray increasing synthesis of vitamin D and lowering risk of thrombus fomation. A systematic review and meta-analysis we performed according PRISMA guidelines. A through literature search was conducted on PubMed, Scopus, and Cochrane database. Total 3 publications match study criteria with 178 samples, without 144 samples and 34 samples with prophylaxis. The overall incidence is 5% (0-6.8%), without 6.25% (5.3-6.8%) and with prophylaxis 0%. No reported complications and 100% survival rate. The incidence of DVT in TBI in tropical climate is low on average 5% (0-6.8%). There was no difference in the outcome of DVT in TBI in tropical climate which given and without DVT prophylaxis. Asian races ethnic protective factor and UV ray exposure may contributed to the low of incidence rate. Prevention of DVT is still recommended for the use of prophylaxis, mechanical compression and early mobilization in cases of TBI to prevent the occurrence of DVT.

Expression malondialdehyde (MDA) of brain after injury with the extract of kencur (Kaempferia Galanga L)

“…The picture of the brain injury research group with a dose of 600 mg Kencur extract showed brown-colored MDA expression with an average count of 0-4 positive cells per 100 neuron cells in the microscope field of view. The picture of the brain injury research group with a dose of 1200 mg Kencur extract showed brown-colored MDA expression with an average cell count of 0-3 positive cells per 100 neuron cells in the microscope field of view (Wido et al, 2022). The results of this study are in line with the research of Mustafa et al which showed that Kencur extract also has antioxidant potential and can reduce MDA expression.…”

Evolution of serum carcinoembryonic antigen in head and neck carcinoma patients

“…Van Dalen et al, 2014 reported that rise in the level of CEA at the time of tumors regression and fall in the level at the time of tumor progression. (16)…”

Benzimidazole-Urea derivatives as anti-cancer agents

“…Ames TA1535 (+S9); rat liver homogenate). Ames TA1535 (-S9); An Ames test done in a lab showed that the TA1535 strain (No metabolic activation) [64][65][66]. Tool of the T.E.S.T program: This is a software program made by the US Environmental Protection Agency to figure out how dangerous a compound is in the short term.…”

“…Cytochrome P450 enzymes are a group of heme proteins that are involved in the metabolism of many pharmacologically active compounds. They can cause unwanted side effects and drug interactions [66,77]. In-silico data show that all of the designed compounds, except for compound SRA19, are substrates for CYP 450 3A4 (non substrate).…”